Patents Assigned to GENRIX (SHANGHAI) BIOPHARMACEUTICAL CO. LTD.
  • ANTIBODY FOR TETANUS TOXIN AND USE THEREOF
    Publication number: 20250129141
    Abstract: Provided are a bispecific antibody and a monoclonal antibody for a tetanus toxin, and uses of the antibodies. The bispecific antibody contains a first antigen-binding fragment and a second antigen-binding fragment which bind to different epitopes of the tetanus toxin, and has activity of neutralizing the tetanus toxin. The monoclonal antibody binds to the tetanus toxin, and has activity of neutralizing the tetanus toxin.
    Type: Application
    Filed: November 19, 2020
    Publication date: April 24, 2025
    Applicants: BEIJING WISDOMAB BIOTECHNOLOGY CO., LTD, GENRIX (SHANGHAI) BIOPHARMACEUTICAL CO. LTD., CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD.
    Inventors: Zhigang LIU, Xiaowei ZHOU, Yulan LIU, Xiaobo HAO, Junjie HU
  • Anti-IL-4R antibody and use thereof
    Patent number: 11897960
    Abstract: Disclosed in the present application are an antibody or an antigen-binding portion thereof binding to human IL-4R, a polynucleotide encoding the antibody or antigen-binding portion thereof, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or vector, a method for preparing and purifying the antibody, and the use of the antibody or antigen-binding portion thereof.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: February 13, 2024
    Assignees: Beijing Wisdomab Biotechnology Co., Ltd, Genrix (Shanghai) Biopharmaceutical Co. Ltd., Chongqing Genrix Biopharmaceutical Co., Ltd.
    Inventors: Zhigang Liu, Yulan Liu, Xiaobo Hao, Lei Jiang, Jingjing Guo
  • Bispecific antibody against rabies virus, and application thereof
    Patent number: 11773155
    Abstract: The present application provides a bispecific antibody against rabies virus, and an application thereof. The bispecific antibody comprises two antigen-binding fragments binding to different epitopes of G protein of rabies virus, and has rabies virus neutralization activity.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: October 3, 2023
    Assignees: Beijing Wisdomab Biotechnology Co., ltd, GENRIX (Shanghai) Biopharmaceutical Co., Ltd., Chongqing GENRIX Biopharmaceutical Co., Ltd.
    Inventors: Zhigang Liu, Xiaobo Hao, Yulan Liu, Jingjing Guo
  • Anti-human IL-17 monoclonal antibodies and use thereof
    Patent number: 10392436
    Abstract: The present application discloses a novel anti-human IL-17 monoclonal antibody obtained by phage antibody library screening and genetic engineering, or a functional fragment thereof, a polynucleotide encoding the monoclonal antibody or the functional fragment thereof, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or vector, a method for preparing and purifying the antibody, and use of the antibody or the functional fragment thereof.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: August 27, 2019
    Assignees: BEIJING BETTERMAB BIOTECHNOLOGY CO., LTD, BEIJING WISDOMAB BIOTECHNOLOGY CO., LTD, GENRIX (SHANGHAI) BIOPHARMACEUTICAL CO. LTD., CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD.
    Inventors: Zhigang Liu, Shijie Shen, Yulan Liu, Jingjing Guo, Xiaobo Hao